Brokerages expect that Chimerix Inc (NASDAQ:CMRX) will announce earnings of ($0.44) per share for the current quarter, Zacks reports. Four analysts have made estimates for Chimerix’s earnings, with the lowest EPS estimate coming in at ($0.46) and the highest estimate coming in at ($0.42). Chimerix posted earnings of ($0.36) per share in the same quarter last year, which suggests a negative year over year growth rate of 22.2%. The business is scheduled to report its next quarterly earnings results on Monday, August 6th.
According to Zacks, analysts expect that Chimerix will report full-year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($1.85) to ($1.64). For the next fiscal year, analysts forecast that the business will report earnings of ($1.71) per share, with EPS estimates ranging from ($2.00) to ($1.20). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Chimerix.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.01. Chimerix had a negative net margin of 1,736.95% and a negative return on equity of 31.97%. The company had revenue of $0.79 million for the quarter, compared to analyst estimates of $1.12 million.
In related news, Director Ernest Mario sold 52,553 shares of the firm’s stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $4.64, for a total transaction of $243,845.92. Following the completion of the sale, the director now directly owns 12,905 shares in the company, valued at $59,879.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 130,368 shares of company stock valued at $616,495 over the last 90 days. 12.50% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of CMRX. Quantitative Systematic Strategies LLC bought a new stake in Chimerix during the first quarter worth approximately $115,000. MetLife Investment Advisors LLC acquired a new position in Chimerix in the 1st quarter worth approximately $127,000. Goldman Sachs Group Inc. acquired a new position in Chimerix in the 4th quarter worth approximately $137,000. Wells Fargo & Company MN boosted its stake in Chimerix by 46.1% in the 1st quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 10,598 shares during the period. Finally, A.R.T. Advisors LLC acquired a new position in Chimerix in the 1st quarter worth approximately $252,000. Hedge funds and other institutional investors own 73.55% of the company’s stock.
Shares of NASDAQ:CMRX traded down $0.21 during trading hours on Friday, hitting $4.61. The stock had a trading volume of 315,940 shares, compared to its average volume of 192,497. Chimerix has a 1-year low of $4.17 and a 1-year high of $5.94. The firm has a market capitalization of $227.31 million, a P/E ratio of -3.05 and a beta of 1.24.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.